Insulin Zinc Suspension (Lente/Ultralente) for Type 1 Diabetes

Mechanism of Action

Insulin zinc suspension consists of insulin crystals complexed with zinc in a neutral-pH buffer. After subcutaneous injection, the crystals dissolve slowly, providing a prolonged, peakless insulin release over 24–48 hours (ultralente) or 12–24 hours (lente).

Pharmacokinetics

  • Onset: 2–4 hours
  • Peak: minimal (ultralente) or 8–12 hours (lente)
  • Duration: up to 24–36 hours (ultralente), 18–24 hours (lente)

Clinical Use

  • Basal insulin coverage in type 1 diabetes (often combined with rapid-acting analogs for meals).
  • Dosing individualized; typically once or twice daily.
  • Requires consistent timing; monitor for hypoglycemia, especially overnight.

Note

Lente and ultralente formulations have largely been replaced by long-acting analogs (glargine, detemir, degludec) which offer more predictable profiles. However, zinc suspensions remain an option where analogs are unavailable or unaffordable.

Diabetes - Related Articles